Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Significant Decline in Short Interest

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the recipient of a large decline in short interest in the month of January. As of January 15th, there was short interest totaling 55,812 shares, a decline of 44.5% from the December 31st total of 100,600 shares. Based on an average trading volume of 1,063,819 shares, the short-interest ratio is presently 0.1 days. Based on an average trading volume of 1,063,819 shares, the short-interest ratio is presently 0.1 days.

Bayer Aktiengesellschaft Stock Performance

OTCMKTS:BAYRY opened at $13.15 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10. Bayer Aktiengesellschaft has a 12-month low of $5.30 and a 12-month high of $13.98. The stock has a market capitalization of $51.75 billion, a P/E ratio of -146.09, a P/E/G ratio of 4.73 and a beta of 0.66. The stock has a 50-day moving average price of $11.02 and a 200 day moving average price of $9.07.

Analyst Ratings Changes

Several analysts have issued reports on BAYRY shares. JPMorgan Chase & Co. raised Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Barclays raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Zacks Research raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 20th. Finally, Morgan Stanley raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. Three investment analysts have rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company. According to MarketBeat.com, Bayer Aktiengesellschaft has a consensus rating of “Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.